|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proximagen's team combines a management of successful entrepreneurs with experienced leading-edge
scientific experts and researchers.
Management Team:
- Chief Executive Officer
Kenneth Mulvany
Kenneth joined Proximagen in March 2004 as Chief Executive and acts to focus the Company's commitment to deliver novel drugs and innovative new treatments for neurodegenerative disease, bringing new hope to patients and value to shareholders.
Prior to joining Proximagen, Kenneth worked in the venture capital markets focused on the biotech and European high-tech industries. Kenneth played key roles in developing several successful high-tech start-ups. He brings 13 years of biotech leadership and experience to Proximagen.
- Chief Scientific Officer
Professor Peter Jenner
As founder and Chief Scientific Officer of Proximagen, Peter is responsible for scientific leadership of Proximagen's research initiatives.
Peter is also a Professor of Pharmacology in the Guy's, King's St Thomas' School of Biomedical Sciences at King's College London. He is the head of the Neurodegenerative Diseases Research Group and a Director of the National Parkinson Foundation Centre of Excellence. In particular, he has contributed to understanding mechanisms involved in the initiation and progression of nigral cell death in Parkinson's disease.
Professor Jenner has published more than 600 papers. He is a frequent speaker at international congresses and to lay groups of patients and caregivers.
- Finance Director
James Hunter
Prior to Proximagen, James spent six years in corporate finance at Ernst & Young where
he worked with a number of fast-growing companies, advsing on financial strategy and
in particular on fund-raising, acquisitions and disposal of assests. James also advised
companies on performance improvement, financial restructuring and working capital
management.
Prior to joining Ernst & Young, James completed the full-time M.B.A programme at Cranfield School of Manangement, following a career in marketing communications.
- Group Director of Drug Development
Bruce Campbell
Bruce joins Proximagen from Neurocrine Biosciences, Inc ("Neurocrine") the NASDAQ listed biotechnology company. Bruce was Senior VP of Development at Neurocine and since 1998 he had overall responsibility for directing Neurocrine's selection and advancement of drug candidates from research into clinical development. This has culminated in advancing eight novel drugs into clinical trials
Bruce has been a Director and European Chairman of the Drug Information Association, a member of the European ICH Safety Working Party and secretary of the Society for Pharmaceutical Medicine.
- Group Director of Biology
Sarah Salvage
Sarah is responsible for biology and operations of preclinical studies at Proximagen. She has extensive experience working with pharmaceutical companies on a variety of programmes focused on neurological diseases.
Sarah received her Ph.D., from University of London and is also a Senior Research Fellow in the Guy's, King's and St Thomas' School of Biomedical Sciences at King's College London.
- Group Director of Chemistry
Chris Hobbs
Chris is responsible for the Chemistry and ADME-PK at Proximagen. He
has more than 15 years experience in the pharmaceutical industry with Roche, Ionix and Proximagen. He is a coinventor of R1479, a prodrug of
which is currently in phase II clinical trials for hepatitis C.
He received his Ph.D., from University College, London and carried out
post-doctoral studies at University of California, Berkeley.
|
|
|
|
|
|
|
